Zacks Research Issues Negative Estimate for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at Zacks Research decreased their Q2 2026 earnings estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings of ($0.75) per share for the quarter, down from their prior estimate of ($0.74). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.54) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q3 2026 earnings at ($0.73) EPS and FY2026 earnings at ($2.90) EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.09. The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $10.00 million. During the same period in the previous year, the firm earned $1.30 EPS. The business’s revenue was down 99.7% on a year-over-year basis.

Several other analysts have also issued reports on the stock. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. JPMorgan Chase & Co. reduced their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Bank of America raised their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.22.

Denali Therapeutics Stock Down 1.1 %

Denali Therapeutics stock opened at $26.15 on Friday. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $32.13. The company has a market cap of $3.73 billion, a P/E ratio of -27.24 and a beta of 1.38. The business has a 50-day simple moving average of $27.10 and a two-hundred day simple moving average of $22.78.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares in the company, valued at $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now directly owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares in the company, valued at $844,656.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. MONECO Advisors LLC grew its holdings in shares of Denali Therapeutics by 4.6% in the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock valued at $265,000 after purchasing an additional 400 shares in the last quarter. CWM LLC grew its stake in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after buying an additional 654 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Denali Therapeutics by 48.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after buying an additional 807 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after buying an additional 920 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Denali Therapeutics by 5.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after acquiring an additional 1,372 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.